Corvus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 28
- Market Cap
- $254.5M
- Website
- http://www.corvuspharma.com
- Introduction
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Conditions
- Systemic Anaplastic Large Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralFollicular T-Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeLymphoma, T-Cell
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06561048
- Locations
- 🇺🇸
Corvus Pharmaceuticals, South San Francisco, California, United States
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT06345404
- Locations
- 🇺🇸
Clinical Site 5, Birmingham, Alabama, United States
🇺🇸Clinical Site 9, Tucson, Arizona, United States
🇺🇸Clinical Site 3, North Little Rock, Arkansas, United States
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
- Conditions
- Covid-19
- Interventions
- Drug: CPI-006 2 mg/kg + SOCDrug: CPI-006 1 mg/kg + SOCDrug: Placebo + SOC
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04734873
- Locations
- 🇺🇸
Sharp Chula Vista Medical Center, Chula Vista, California, United States
🇺🇸El Centro Regional Medical Center, El Centro, California, United States
🇺🇸Sharp Grossmont Hospital, La Mesa, California, United States
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04464395
- Locations
- 🇺🇸
El Centro Regional Medical Center, El Centro, California, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Temple University Hospital, Philadelphia, Pennsylvania, United States
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04280328
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- Prev
- 1
- 2
- Next
News
IL-2 Inhibitor Pipeline Expands with 20+ Companies Developing 22+ Therapeutic Candidates
DelveInsight's 2025 pipeline report reveals over 20 pharmaceutical companies are actively developing 22+ interleukin-2 inhibitor drugs across various clinical stages.
Angel Pharmaceuticals Receives China IND Approval for Soquelitinib Atopic Dermatitis Trial
Angel Pharmaceuticals received IND approval from China's NMPA to initiate a Phase 1b/2 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis treatment.
Robust Pipeline of 50+ Therapies Reshaping Moderate to Severe Atopic Dermatitis Treatment Landscape
• The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition. • Recent advancements include promising biologics like rezpegaldesleukin (granted FDA fast-track designation), JAK inhibitors such as VC005 and QY201, and novel mechanisms targeting IL-4/IL-13 pathways, offering new hope for patients with inadequate response to current treatments. • Key players including Nektar Therapeutics, Corvus Pharmaceuticals, and Apogee Therapeutics are advancing clinical trials with significant milestones expected in late 2025, potentially transforming the therapeutic landscape for this chronic inflammatory skin condition.
Corvus Pharmaceuticals Initiates Phase 2 Trial of Soquelitinib for Rare Genetic Disease ALPS
NIH/NIAID has launched a Phase 2 clinical trial of Corvus Pharmaceuticals' soquelitinib for autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease typically manifesting by age two.
Adenosine Antagonists Show Promise in Clinical Trials for Cancer and COPD
• Adenosine antagonists are under investigation for novel therapeutic applications in neurodegenerative diseases, oncology, and cardiovascular disorders. • Several companies, including Arcus Biosciences and Corvus Pharmaceuticals, are advancing adenosine antagonists through clinical trials to improve treatment landscapes. • Clinical trials are evaluating drugs like etrumadenant, ciforadenant and PBF-680 in various phases for conditions like colorectal cancer, prostate cancer and COPD.
Corvus Pharmaceuticals' Soquelitinib Shows Promise in Phase 1 Atopic Dermatitis Trial
Corvus Pharmaceuticals' Phase 1 trial of soquelitinib for atopic dermatitis shows a favorable safety and efficacy profile.
Corvus Pharmaceuticals Advances Soquelitinib Trials and Reports Q3 2024 Financials
Corvus Pharmaceuticals is progressing Phase 3 trials for soquelitinib in Peripheral T Cell Lymphoma (PTCL) and Phase 1 trials for atopic dermatitis, with interim data expected in December 2024.
Ciforadenant Shows Promise in Overcoming Immunotherapy Resistance in Prostate Cancer
New data suggests ciforadenant, an adenosine A2A receptor antagonist, can enhance sensitivity to anti-PD1 therapy in metastatic castration-resistant prostate cancer (mCRPC).
Ciforadenant Shows Promise in Overcoming Immunotherapy Resistance in Prostate Cancer
New data suggests ciforadenant, an adenosine A2A receptor antagonist, can overcome resistance to anti-PD1 immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).
Ciforadenant Shows Promise in Overcoming Immunotherapy Resistance in Prostate Cancer
Corvus Pharmaceuticals' ciforadenant, an adenosine A2A receptor antagonist, demonstrates potential in overcoming resistance to anti-PD1 immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).